SecBot SecBot
SECBOTREPLAY Home › Report › CYTK

CYTK · Q3 rev $47.6M, EPS -$1.37

Cytokinetics, Incorporated · PRESS-RELEASE filed Nov 4, 2026 at 16:00 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Nov 4, 2026 at 16:00 ET

Cytokinetics reported Q3 2026 revenue of $47.6M, driven by $44.5M in MYQORZO net product revenue, beating the $42.3M consensus. EPS of -$1.37 beat the -$1.41 consensus. The company reaffirmed full-year 2026 guidance and plans to file a supplemental NDA for aficamten in non-obstructive HCM in Q4 2026.

  • Total revenues $47.6M vs $1.9M YoY, consensus $42.3M
  • MYQORZO net product revenue $44.5M ($43.1M U.S., $1.4M Europe)
  • EPS -$1.37 vs consensus -$1.41 (beat)
  • Net loss $190.1M vs $306.2M YoY

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access